tiprankstipranks
BioNexus Gene Lab Corp (BGLC)
NASDAQ:BGLC
US Market

BioNexus Gene Lab Corp (BGLC) Stock Price & Analysis

51 Followers

BGLC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.31 - $17.90
Previous Close$0.58
Volume108.30K
Average Volume (3M)251.70K
Market Cap
$10.25M
Enterprise Value$5.73M
Total Cash (Recent Filing)$4.70M
Total Debt (Recent Filing)$138.76K
Price to Earnings (P/E)-3.6
Beta0.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding17,667,663
10 Day Avg. Volume59,056
30 Day Avg. Volume251,697
Standard Deviation0.32
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.06
Price to Sales (P/S)3.63
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.55
Enterprise Value/Gross Profit4.55
Enterprise Value/Ebitda-1.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.13%0.34%99.53%
0.00%
Insiders
0.34% Other Institutional Investors
99.53% Public Companies and
Individual Investors

BGLC FAQ

What was BioNexus Gene Lab Corp’s price range in the past 12 months?
BioNexus Gene Lab Corp lowest stock price was $0.31 and its highest was $17.90 in the past 12 months.
    What is BioNexus Gene Lab Corp’s market cap?
    Currently, no data Available
    When is BioNexus Gene Lab Corp’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were BioNexus Gene Lab Corp’s earnings last quarter?
    Currently, no data Available
    Is BioNexus Gene Lab Corp overvalued?
    According to Wall Street analysts BioNexus Gene Lab Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does BioNexus Gene Lab Corp pay dividends?
      BioNexus Gene Lab Corp does not currently pay dividends.
      What is BioNexus Gene Lab Corp’s EPS estimate?
      BioNexus Gene Lab Corp’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does BioNexus Gene Lab Corp have?
      BioNexus Gene Lab Corp has 17,667,664 shares outstanding.
        What happened to BioNexus Gene Lab Corp’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of BioNexus Gene Lab Corp?
        Currently, no hedge funds are holding shares in BGLC
        ---

        BioNexus Gene Lab Corp Stock Smart Score

        N/A
        Not Ranked
        1
        2
        3
        4
        5
        6
        7
        8
        9
        10

        Technicals

        SMA
        Negative
        20 days / 200 days
        Momentum
        -82.35%
        12-Months-Change

        Fundamentals

        Return on Equity
        -32.21%
        Trailing 12-Months
        Asset Growth
        30.43%
        Trailing 12-Months

        Company Description

        BioNexus Gene Lab Corp

        BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
        ---
        Similar Stocks
        Company
        Price & Change
        Follow
        BeiGene
        Biocept
        Crispr Therapeutics AG
        Popular Stocks
        ---
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis